Professor Michael Barry:

This is a big issue. For up to 40% of orphan drugs we do not have an application for pricing reimbursement. I cannot do anything about that; I honestly cannot. It is probably to do with finances, as Deputy Buckley was saying earlier. Why do they not launch here? They launch in big markets where they get more resources, essentially. That is an issue. I get Ms McGrath's frustration with this but we cannot assess a drug if there is no reimbursement application, unfortunately.